ANI Pharmaceuticals (NASDAQ:ANIP) posted its earnings results on Tuesday. The specialty pharmaceutical company reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.12, Fidelity Earnings reports. ANI Pharmaceuticals had a return on equity of 27.76% and a net margin of 0.06%. The firm had revenue of $50.70 million during the quarter, compared to analysts’ expectations of $50.97 million. During the same period in the previous year, the firm earned $1.11 earnings per share. The company’s revenue was up 5.3% on a year-over-year basis. ANI Pharmaceuticals updated its FY18 guidance to $4.80-5.27 EPS.
Shares of ANIP stock traded up $0.83 on Wednesday, hitting $54.35. 2,858 shares of the stock were exchanged, compared to its average volume of 68,339. The company has a debt-to-equity ratio of 1.08, a current ratio of 3.84 and a quick ratio of 2.89. The stock has a market capitalization of $613.94 million, a P/E ratio of 15.06 and a beta of 2.64. ANI Pharmaceuticals has a fifty-two week low of $48.40 and a fifty-two week high of $74.70.
Several hedge funds have recently bought and sold shares of the company. Sei Investments Co. raised its holdings in ANI Pharmaceuticals by 56.9% during the first quarter. Sei Investments Co. now owns 2,252 shares of the specialty pharmaceutical company’s stock worth $131,000 after acquiring an additional 817 shares in the last quarter. Bessemer Group Inc. bought a new stake in ANI Pharmaceuticals in the third quarter valued at approximately $138,000. Piedmont Investment Advisors LLC bought a new stake in ANI Pharmaceuticals in the second quarter valued at approximately $140,000. Truvestments Capital LLC bought a new stake in ANI Pharmaceuticals in the third quarter valued at approximately $152,000. Finally, Stifel Financial Corp bought a new stake in ANI Pharmaceuticals in the first quarter valued at approximately $215,000. 61.10% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This article was reported by Week Herald and is the property of of Week Herald. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://weekherald.com/2018/11/07/ani-pharmaceuticals-anip-issues-earnings-results.html.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.
Read More: Marijuana Stocks Future Looks Bright
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.